Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chau Dang

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
Breast Cancer Research and Treatment|January 5, 2021
Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart functionKatia Khoury, Filipa Lynce, Ana Barac, et al.
Cancer Research|August 5, 2016
Exercise and Prognosis on the Basis of Clinicopathologic and Molecular Features in Early-Stage Breast Cancer: The LACE and Pathways StudiesLee W Jones, Marilyn L Kwan, Erin Weltzien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2008
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancerChau Dang, Monica Fornier, Steven Sugarman, et al.
Histopathology|March 5, 2024
A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on Cancer Reporting (ICCR)Veerle Bossuyt, Elena Provenzano, W Fraser Symmans, et al.
JAMA Oncology|November 6, 2015
Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast CancerChau Dang, Hao Guo, Julie Najita, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2020
Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast CancerAranzazu Fernandez-Martinez, Ian E Krop, David W Hillman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2009
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancerTiffany A Traina, Hope S Rugo, James F Caravelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2011
A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancerHeather L McArthur, Hope Rugo, Benjamin Nulsen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 22, 2019
NCCN Guidelines Insights: Breast Cancer, Version 3.2018Matthew P Goetz, William J Gradishar, Benjamin O Anderson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 8, 2020
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in OncologyWilliam J Gradishar, Benjamin O Anderson, Jame Abraham, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Breast Cancer Research and Treatment|January 5, 2021
Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart functionKatia Khoury, Filipa Lynce, Ana Barac, et al.
Cancer Research|August 5, 2016
Exercise and Prognosis on the Basis of Clinicopathologic and Molecular Features in Early-Stage Breast Cancer: The LACE and Pathways StudiesLee W Jones, Marilyn L Kwan, Erin Weltzien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2008
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancerChau Dang, Monica Fornier, Steven Sugarman, et al.
Histopathology|March 5, 2024
A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on Cancer Reporting (ICCR)Veerle Bossuyt, Elena Provenzano, W Fraser Symmans, et al.
JAMA Oncology|November 6, 2015
Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast CancerChau Dang, Hao Guo, Julie Najita, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2020
Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast CancerAranzazu Fernandez-Martinez, Ian E Krop, David W Hillman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2009
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancerTiffany A Traina, Hope S Rugo, James F Caravelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2011
A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancerHeather L McArthur, Hope Rugo, Benjamin Nulsen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 22, 2019
NCCN Guidelines Insights: Breast Cancer, Version 3.2018Matthew P Goetz, William J Gradishar, Benjamin O Anderson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 8, 2020
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in OncologyWilliam J Gradishar, Benjamin O Anderson, Jame Abraham, et al.
Pageof 8